C. PRACHAR ET AL. 307
duced when the stored and mature neutrophils are used
up. This can be seen in blood analyzes when the amount
of the so-called banded neutrophils increases compared
to the mature and segmented neutrophils.
Detectable amounts of IL-1β are correlated with any
inflammatory reaction. Still, there appears to be a very
limited period of time in which free IL-1β can be de-
tected in the serum. This unfortunate fact is the reason
why IL-1β is not used in common diagnosis.
Diagnostic techniques with a higher sensitivity like the
ones with lower concentration ranges may be more ap-
propriate for measurements of IL-1β in the serum. Even
if measurements with a human ELISA showed good re-
sults, a specific ELISA for canine IL-1β could lead to
better results.
Further studies on a larger population could find evi-
dence that IL-1β perhaps is a useful marker for early
stages of inflammation, comparable to the fact that the
grade of leukocytosis is a good parameter to assess the
stage of inflammation.
REFERENCES
[1] C. A. Dinarello, “Biologic Basis for Interleukin-1 in Dis-
ease,” Blood, Vol. 87, No. 6, 1996, pp. 2095-2147.
[2] J. L. Telford, G. Macchia, A. Massone, V. Carinci, E.
Palla and M. Melli, “The Murine Interleukin 1 Beta Gene:
Structure and Evolution,” Nucleic Acids Research, Vol.
14, No. 24, 1986, pp. 9955-9963.
http://dx.doi.org/10.1093/nar/14.24.9955
[3] P. L. Kilian, K. L. Kaffka, A. S. Stern, D. Woehle, W. R.
Benjamin, T. M. Dechiara, U. Gubler, J. J. Farrar, S. B.
Mizel and P. T. Lomedico, “Interleukin 1 Alpha and In-
terleukin 1 Beta Bind to the Same Receptor on T Cells,”
The Journal of Immunology, Vol. 136, No. 12, 1986, pp.
4509-4514.
[4] C. A. Meyers, K. O. Johanson, L. M. Miles, P. J. McDe-
vitt, P. L. Simon, R. L. Webb, M. J. Chen, B. P. Holskin,
J. S. Lillquist and P. R. Young, “Purification and Charac-
terization of Human Recombinant Interleukin-1 Beta,”
The Journal of Biological Chemistry, Vol. 262, No. 23,
1987, pp. 11176-11181.
[5] S. K. Durum, J. A. Schmidt and J. J. Oppenheim, “Inter-
leukin 1: An Immunological Perspective,” Annual Review
of Immunology, Vol. 3, No. 1, 1985, pp. 263-287.
http://dx.doi.org/10.1146/annurev.iy.03.040185.001403
[6] C. A. Dinarello, “Interleukin-1 and the Pathogenesis of
the Acute-Phase Response,” The New England Journal of
Medicine, Vol. 311, No. 22, 1984, pp. 1413-1418.
http://dx.doi.org/10.1056/NEJM198411293112205
[7] F. Ceciliani, A. Giordano and V. Spagnolo, “The Syste-
mic Reaction during Inflammation: The Acute-Phase Pro-
teins,” Protein and Peptide Letters, Vol. 9, No. 3, 2002,
pp. 211-223.
http://dx.doi.org/10.2174/0929866023408779
[8] A Grone, S. Fonfara and W. Baumgartner, “Cell Type-
Dependent Cytokine Expression after Canine Distemper
Virus Infectio,” Viral Immunology, Vol. 15, No. 3, 2002,
pp. 493-505.
http://dx.doi.org/10.1089/088282402760312368
[9] M. F. Rai, P. S. Rachakondaa, K. Manning, B. Vorwerk,
L. Brunnberg, B. Kohn, M. F. G. Schmidt, “Quantifica-
tion of Cytokines and Inflammatory Mediators in a Three-
Dimensional Model of Inflammatory Arthritis,” Cytoki ne,
Vol. 42, No. 1, 2008, pp. 8-17.
http://dx.doi.org/10.1016/j.cyto.2008.02.004
[10] J. Y. Yhee, C.-H. Yu, J.-H. Kim and J.-H. Sur1, “Effects
of T Lymphocytes, Interleukin-1, and Interleukin-6 on
Renal Fibrosis in Canine End-Stage Renal Disease,”
Journal of Veterinary Diagnostic Investigation, Vol. 20,
No. 5, 2008, pp. 585-592.
http://dx.doi.org/10.1177/104063870802000508
[11] K. K. Al’tsivanovich and V. N. Gurin, “Activity of Blood
Interleukin-1 in Dogs during Work Hyperthermia,” Bulle-
tin of Experimental Biology and Medicine, Vol. 110, No.
12, 1990, pp. 565-567.
[12] J. T. Soller, H. Murua-Escobar, S. Willenbrock, M.
Janssen, N. Eberle, J. Bullerdiek and I. Nolte, “Compari-
son of the Human and Canine Cytokines IL-1 (Al-
pha/Beta) and TNF-Alpha to Orthologous Other Mam-
malians,” Journal of Heredity, Vol. 98, No. 5, 2007, pp.
485-490.
http://dx.doi.org/10.1093/jhered/esm025
[13] T. Miyamoto, T. Fujinaga, K. Yamashita and M. Hagio,
“Changes of Serum Cytokine Activities and Other Pa-
rameters in Dogs with Experimentally Induced Endotoxic
Shock,” The Japanese Journal of Veterinary Research,
Vol. 44, No. 2, 1996, pp. 107-118.
[14] V. Barak, C. Selmi, M. Schlesinger, M. Blank, N. Ag-
mon-Levin, I. Kalickman, M. E. Gershwin and Y. Shoen-
feld, “Serum Inflammatory Cytokines, Complement Com-
ponents, and Soluble Interleukin 2 Receptor in Primary
Biliary Cirrhosis,” Journal of Autoimmunity, Vol. 33, No.
3-4, 2009, pp. 178-182.
http://dx.doi.org/10.1016/j.jaut.2009.09.010
[15] E. A. Fernandez-Figueroa, et al., “Disease Severity in
Patients Infected with Leishmania Mexicana Relates to
IL-1β,” PLOS Neglected Tropical Diseases, Vol. 6, No. 5,
2012, p. E1533.
[16] B. Brugos, Z. Vincze, S. Sipka, G. Szegedi and M. Zeher,
“Serum and Urinary Cytokine Levels of SLE Patients,”
Pharmazie, Vol. 67, No. 5, 2012, pp. 411-413.
[17] S. Papin, S. Cuenin1, L. Agostini1, F. Martinon1, S. Wer-
ner, H.-D. Beer, C. Grütter, M. Grütter and J. Tschopp,
“The SPRY Domain of Pyrin, Mutated in Familial Medi-
terranean Fever Patients, Interacts with Inflammasome
Components and Inhibits Proil-1β Processing,” Cell
Death and Differentiation, Vol. 14, No. 8, 2007, pp.
1457-1466. http://dx.doi.org/10.1038/sj.cdd.4402142
[18] S. M. Allan, P. J. Tyrrell and N. J. Rothwell, “Interleu-
kin-1 and Neuronal Injury,” Nature Reviews Immunology,
Vol. 5, No. 8, 2005, pp. 629-640.
http://dx.doi.org/10.1038/nri1664
[19] M. Kusuhara, K. Isoda and F. Ohsuzu, “Interleukin-1 and
Occlusive Arterial Diseases,” Cardiovascular & Hema-
tological Agents in Medicinal Chemistry, Vol. 4, No. 3,
Open Access OJVM